If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Vatiquinone (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name, JANTooltip Japanese Accepted Name), also known as α-tocotrienol quinone or vincerenone and by its developmental code names EPI-743 and PTC-743, is a synthetic analogue of coenzyme Q10, antioxidant, and oxidoreductase inhibitor which is under development for the treatment of Friedreich's ataxia, mitochondrial disorders, epilepsy, Leigh disease, methylmalonic acidemia, noise-induced hearing loss, Parkinson's disease, Rett syndrome, and Tourette's syndrome. It is taken orally. The drug inhibits 15-lipoxygenase (15-LOX; ALOX15) and/or other oxidoreductases, enzymes involved in inflammation, ferroptosis, and oxidative stress. It has also been described as a selective 15-LOX inhibitor however. The antioxidant activities of vatiquinone are said to be 1,000- to 10,000-fold greater than those of resveratrol, idebenone, or coenzyme Q10. Mitochondrial dysfunction results in excessive production of reactive oxygen and reactive nitrogen species, which causes redox imbalance and glutathione deficiency. Vatiquinone may increase intracellular glutathione levels and thereby theoretically improve redox balance to treat mitochondrial disorders. Vatiquinone is or has been under development by Edison Pharmaceuticals and PTC Therapeutics, among other organizations.
== Regulation == Like other drugs, botanical drugs may be sold over the counter (OTC) or by prescription only. For OTC drugs, a monograph must be created by the company that wants to market the drug and then approved by the FDA, after which it is published in the Federal Register. For prescription drugs, a New Drug Application (NDA) must be filed with and approved by the FDA; clinical data included in the NDA is gathered under an Investigational New Drug Application which the FDA also must approve before clinical testing begins. Assessment of the safety and toxicity of botanical drugs in clinical trials, and in ensuring their quality once the drug is on the market, is complicated by the nature of the raw ingredients; problems arise in identifying the correct plants to harvest, in the quality of plants harvested, in their processing, and in the stability of the active components, which are often poorly understood. The FDA relies on a combination of tests and controls to ensure the identity and quality of botanical drugs. The tests include "fingerprinting" using spectroscopy or chromatography, chemical or biological assays, and process controls on raw material collection and processing. The standards are higher for botanical drugs than for extracts or plant matter used in dietary supplements. If the substance being developed as a botanical drug has been used in traditional medicine, it may be possible to begin initial, small clinical trials without conducting extensive toxicology testing.
== Products == In terms of molecular structure, one distinguishes first between low-molecular-weight (LMW) and high-molecular-weight (HMW) products. The generally accepted threshold between LMW and HMW is a molecular weight of about 700 g/mol. LMW fine chemicals, also designated as small molecules, are produced by traditional chemical synthesis, by microorganisms (through fermentation or biotransformation), or by extraction from plants and animals. In the production of modern life science products, total synthesis from petrochemicals prevails. HMW products, or large molecules, are obtained mainly through biotechnology processes. Within LMWs, the N-heterocyclic compounds are the most important category; within HMWs, it is peptides and proteins.
== Treatment == The one known curative treatment is allogeneic stem cell transplantation, but this approach involves significant risks. Other treatment options are largely supportive, and do not alter the course of the disorder (with the possible exception of ruxolitinib, as discussed below). These options may include regular folic acid, allopurinol or blood transfusions. Dexamethasone, alpha-interferon and hydroxyurea (also known as hydroxycarbamide) may play a role. Lenalidomide and thalidomide may be used in its treatment, though peripheral neuropathy is a common troublesome side-effect. Splenectomy is sometimes considered as a treatment option for patients with myelofibrosis in whom massive splenomegaly is contributing to anaemia because of hypersplenism, particularly if they have a heavy requirement for blood transfusions. However, splenectomy in the presence of massive splenomegaly is a high-risk procedure, with a mortality risk as high as 3% in some studies. In November 2011, the US Food and Drug Administration (FDA) approved ruxolitinib (Jakafi) as a treatment for intermediate or high-risk myelofibrosis. Ruxolitinib serves as an inhibitor of JAK 1 and 2. Data from two phase III studies of ruxolitinib showed that the treatment significantly reduced spleen volume, improved symptoms of myelofibrosis, and was associated with much improved overall survival rates compared to placebo. However, the beneficial effect of ruxolitinib on survival has been recently questioned.
Sinosauropteryx (meaning "Chinese reptilian wing") is an extinct genus of coelurosaurian theropod dinosaurs. Described in 1996, it was the first dinosaur taxon outside of Avialae (birds and their immediate relatives) to be found with evidence of feathers. It was covered with a coat of very simple filament-like feathers. Structures that indicate the colour pattern have also been preserved in some of its feathers, which show that Sinosauropteryx had a countershading pattern in its body with a banded tail. The reddish brown colouration previously inferred for Sinosauropteryx is based on the melanosomes preserved in the specimen of a separate genus, Huadanosaurus. Some contention has arisen with an alternative interpretation of the filamentous impression as remains of collagen fibres, but this has not been widely accepted. Sinosauropteryx was a small theropod with an unusually long tail and short arms. The longest known specimen reaches up to 1.07 metres (3.51 feet) in length, with an estimated weight of 0.55 kilograms (1.21 pounds). It was considered a close relative of the similar but older genus Compsognathus, with both genera belonging to the family Compsognathidae, though subsequent analyses did not recover this family to be monophyletic and placed Sinosauropteryx within its own family, Sinosauropterygidae. Two species of Sinosauropteryx have been named. The first, S. prima, is known from three specimens, named "first" in reference to its status as the first feathered non-avian dinosaur species discovered.
Sources: en.wikipedia.org
== Additional facts == On Malacards, it has an information score of 7/100. There are currently no known genes or related disorders related to chondronectins. There are no current therapeutics, variations, expressions, pathways, GO terms or genetic tests for chondronectins currently. Chondronectin has been described as a trimeric glycoprotein with compact globular properties. The protein has most commonly been detected in cartilage related fluids such as synovial fluid and plasma. Chondronectin functions primarily as an attachment factor between chondrocytes and collagen based matrix materials. Most currently available information on chondronectin comes from isolation and characterization studies completed during the 1980s.
The town is littered with traps the player can utilize to kill zombies, built by the town's lone inhabitant, Father Grigori. The player follows him to the town's warehouse district; Grigori gives the player a shotgun and directs him to a cemetery. Grigori helps the player enter a nearby crypt, holding off incoming zombies in a last stand. The player continues on through a series of mines, escaping via a railway network to reach Shorepoint, a Resistance outpost.
== Drug targeting == Certain antibiotics, such as tetracyclines, prevent the aminoacyl-tRNA from binding to the ribosomal subunit in prokaryotes. It is understood that tetracyclines inhibit the attachment of aa-tRNA within the acceptor (A) site of prokaryotic ribosomes during translation. Tetracyclines are considered broad-spectrum antibiotic agents; these drugs exhibit capabilities of inhibiting the growth of both gram-positive and gram-negative bacteria, as well as other atypical microorganisms. Furthermore, the TetM protein (P21598) is found to allow aminoacyl-tRNA molecules to bind to the ribosomal acceptor site, despite being concentrated with tetracyclines that would typically inhibit such actions. The TetM protein is regarded as a ribosomal protection protein, exhibiting GTPase activity that is dependent upon ribosomes. Research has demonstrated that in the presence of TetM proteins, tetracyclines are released from ribosomes. Thus, this allows for aa-tRNA binding to the A site of ribosomes, as it is no longer precluded by tetracycline molecules. TetO is 75% similar to TetM, and both have some 45% similarity with EF-G. The structure of TetM in complex with E. coli ribosome has been resolved.
The carbon footprint of cattle rearing (see environmental impact of meat production) Use of chemicals in the tanning process (e.g., chromium, phthalate esters, nonyl phenol ethoxylate soaps, pentachlorophenol and solvents) Air pollution due to the transformation process (hydrogen sulfide is formed during mixing with acids and ammonia liberated during deliming, solvent vapors)
Sources: en.wikipedia.org
Maúrtua further added that Castillo met Maduro during the VI Summit of CELAC, where many Latin American leaders were present. The Foreign Minister stated that in such multilateral events, spontaneous meetings are natural. Subsequently, the Free Peru caucus accused Maúrtua of trying to impose his political agenda on the President, and called for Maúrtua's resignation: "The foreign minister remained silent... in the face of the audacity of his Vice Foreign Minister Luis Enrique Chávez to contradict the president in his decision to maintain friendly relations and cooperation with Venezuela and the Maduro government. Therefore, having transgressed the provisions of Article 118, paragraph 11 of the Political Constitution, our caucus demands the resignation of both the minister and the vice minister." On 15 October 2021, following the appointment of the Vásquez cabinet, Richard Rojas Garcia was appointed as Peru's ambassador to Venezuela. This in effect established official diplomatic relations with Venezuela. Some media outlets have claimed that Rojas is the right-hand man of Vladimir Cerrón. However, soon afterward a judge ruled that Rojas could not leave the country for 6 months, due to his alleged link with members of "Los Dinámicos del Centro." Afterward, Foreign Minister Óscar Maúrtua claimed that Rojas' appointment as ambassador to Venezuela never took place, "since the corresponding process was not concluded. In this sense, Peru is proceeding to inform the Government of Venezuela that the proposed appointment of Mr.
It is possible to distinguish these sources by analyzing this oil by high-temperature gas chromatography–mass spectrometry. The oil and plasticizer must be separated from the C-4 sample, typically by using a non-polar organic solvent such as pentane followed by solid phase extraction of the plasticizer on silica. This method of analysis is limited by manufacturing variation and methods of distribution.
On August 22, 2018, Alice in Chains sent fans on a scavenger hunt to access a secret gig that the band would be performing in Seattle on August 24. Ten signed CD copies of Rainier Fog were hidden around the city as a ticket into the show, and the band asked the fans to keep an eye on their Instagram story for details on the 10 hidden locations. Once all 10 albums were found, the band revealed that the secret gig would be at the rock club The Crocodile, with limited tickets available with the purchase of their album at a pop-up event at the same venue the next day. Preview clips of each of the album tracks were posted on the band's Instagram. The band also commemorated the release of the album with a pop-up museum installation at The Crocodile in Seattle on August 23 and 24. The museum featured rare Alice in Chains photos, limited-edition merchandise and memorabilia that showcased the band's 30+ year career. Rainier Fog debuted at No. 12 on the Billboard 200 chart, selling 31,000 copies (29,000 in traditional album sales), in its first week of release. The album also debuted at No. 1 on Billboard's Top Rock Albums, Alternative Albums and Hard Rock Albums charts, and at No. 3 on the Vinyl Albums chart. Rainier Fog became Alice in Chains' first top 10 in the UK, peaking at No. 9, and topping UK's Rock & Metal Albums chart. The album has been nominated for a Grammy Award for Best Rock Album.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.